Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

It’s a shot at better health that comes with a promise to help shed the pounds. Demand for drugs like Ozempic, Wegovy, Mounjaro and Zepbound continues to grow. FILE – Donna ...